Higher percentage of strut coverage in biodegradable polymer DES vs. durable polymer DES. Strut level OCT analyses

Original title: Randomized comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis. Reference:  EuroIntervention 2014; 9-online publish-ahead-of-print February 2014

 

The aim of this study was to compare strut coverage at six months follow up after Nobori biolimus eluting stent (N- BES) implantation versus Cypher Select sirolimus eluting stent (SES) implantation.

A total of 120 patients with a single stenotic lesion requiring revascularization were randomly assigned to either N-BES (n=60) or SES (n=60). Optical coherence tomography (OCT) was performed post stent implantation, and at six months follow-up. Post-intervention and follow-up OCT analyses were available in 51 (85.0%) and 52 (86.7%) patients, respectively. 

Primary endpoint was the percentage of uncovered struts at 6 months. In addition, an OCT contour plot analysis was constructed to investigate the distribution patterns of uncovered struts. 

The percentage of uncovered struts of N-BES was significantly lower versus SES (15.9±12.2% versus 25.1±18.3%, respectively, p=0.003). N-BES showed a greater NIH thickness than SES (median [interquartile range] 52.4 μm [41.9-74.9] versus 42.1 μm [30.6-56.0], p=0.005).   

Contour plot analyses by OCT showed a lower incidence of a diffuse distribution pattern of uncovered struts in N- BES versus SES (46.8% versus 75.0%, respectively, p=0.022). 

Conclusions:

This randomized OCT study showed that N-BES had a significantly lower percentage of uncovered struts than SES, and less common diffuse distribution pattern of uncovered struts. 

Editorial Comment

This randomized study reinforces the shared idea that biodegradable polymer drug eluting stents are safer. Chronic endothelial inflammation produced by polymers seems significantly less severe. For the first time, a large randomized BES vs SES study with OCT was performed showing that uncovered strut percentage at six months is significantly lower in BES.

Even though major adverse events were not observed in this study, we could infer that patients with BES, with a lower uncovered strut rate and therefore a lower stent thrombosis rate, due to early discontinuation of the dual antiplatelet therapy, would benefit in the long term.

It seems logical to assume the role of biodegradable polymer drug eluting stents as the safest alternative, with no less efficacy. Further analysis is required to assess the safety and efficacy of bioresorbable stents.

Courtesy of Dr. Matías Sztejfman.
Interventional Cardiologist.
Güemes Hospital. Buenos Aires, Argentina.

Dr. Matías Sztejfman

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...